[Birgitta-A]

Hi Linda,
You have already got very good info from Dan and Greg I will only show very short results from the studies:

Sapacitabine
Patients: High risk MDS treated with Vidaza or Dacogen
Response: 35% when the patients received 300mg b i d x 7 days
Adverse effects: low counts in all three cell lines

Estybon
Patients: High risk MDS treated with Vidaza or Dacogen
Response: 54%
Adverse effects: No suppression of the bone marrow

Then we know that because MDS isn't one disease but many we don't know who will respond (yet) as Greg wrote.
Kind regards
Birgitta-A